文献速递前列腺癌

ASIST试验:主动监测中MRI靶向联合系统活检与系统活检的2年随访随机研究

Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.
PubMed 文献 · Eur Urol · 2019-11-08

ASIST试验前瞻性随机纳入Gleason1级前列腺癌主动监测患者,比较确认活检前MRI靶向联合系统活检与单纯系统活检。2年随访显示MRI组主动监测失败率19%低于非MRI组35%(p=0.017),2年活检临床显著癌比例MRI组9.9%低于非MRI组23%(p=0.048)。

要点

  • 确认活检前基线MRI可减少主动监测失败和分级进展
  • MRI组2年临床显著癌比例9.9%低于非MRI组23%
  • MRI和靶向活检实施中心可能影响监测失败率

核心结论

  • 确认活检前基线MRI使2年内主动监测失败减少50%并减少分级进展。
  • MRI和靶向活检实施的中心可能影响主动监测失败率。

研究设计与样本

  • ASIST为前瞻性随机多中心开放标签研究,纳入适合主动监测的Gleason分级组1级前列腺癌患者。
  • 259例患者接受确认活检,非MRI组132例,MRI组127例。

主要发现

  • 确认活检后非MRI组101例(76%)和MRI组98例(77%)继续主动监测。
  • MRI组主动监测失败19/98(19%),非MRI组35/101(35%),p=0.017。
  • 2年活检MRI组临床显著癌9.9%(8/81),非MRI组23%(17/75),p=0.048。
  • MRI组三个中心间主动监测失败率差异显著(4.2%[2/48] vs 17%[4/24] vs 27%[7/26],p=0.019)。

关键数值与推荐

  • 临床显著癌定义为Gleason分级组≥2。
  • 主动监测失败定义为因分级进展、临床进展、受试者选择、临床判断、治疗或失访而不再主动监测。

临床怎么用

  • 主动监测患者在确认活检前可考虑基线MRI以降低监测失败和分级进展风险。
  • MRI和靶向活检的实施中心可能影响监测结局,需关注操作质量。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The initial report from the ASIST trial showed little benefit from targeted biopsy for men on active surveillance (AS) for prostate cancer. Data after 2-yr follow-up are now available for analysis. OBJECTIVE: To determine if there was a difference in the AS failure rate in a 2-yr follow-up period among men undergoing magnetic resonance imaging (MRI) before initial confirmatory biopsy (CBx) compared to those who did not. DESIGN, SETTING, AND PARTICIPANTS: This is the 2-yr post-CBx follow-up for the ASIST trial, a prospective, randomized, multicenter, open-label study for men with Gleason grade group (GG) 1 cancer eligible for AS. Patients were randomized to CBx with 12-core systematic sampling or MRI with systematic and targeted sampling. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients with GG ≤ 1 on CBx were followed for 2 yr and had MRI and biopsy at that time point. Patients failed AS if they were no longer under AS because of grade progression, clinical progression, subject choice, clinical judgment, treatment, or lost to follow-up. Clinically significant cancer (CSC) was defined as GG ≥ 2. RESULTS AND LIMITATIONS: In total, 259 men underwent CBx, 132 in the non-MRI and 127 in the MRI arm. After biopsy, 101 men in the non-MRI arm (76%) and 98 in the MRI arm (77%) continued AS. There were fewer men with AS failures in the MRI (19/98, 19%) compared to the non-MRI group (35/101, 35%; p = 0.017). At 2-yr biopsy there were fewer men with CSC in the MRI arm (9.9%, 8/81) than in the non-MRI arm (23%, 17/75; p = 0.048). Significant differences in AS failure rates were detected across the three centers in the MRI arm only (4.2% [2/48] vs 17% [4/24] vs 27% [7/26]; p = 0.019). CONCLUSIONS: Baseline MRI before CBx during AS results in 50% fewer AS failures and less grade progression over 2 yr. The center where MRI and targeted biopsy is performed may influence AS failure rates. PATIENT SUMMARY: The ASIST trial randomized 273 men on active surveillance with low-grade prostate cancer diagnosed within the last year to systematic biopsy or magnetic resonance imaging (MRI) with systematic and targeted biopsy. The initial report showed little benefit from targeted biopsy. However, after 2 yr of follow-up we found that baseline MRI before confirmatory biopsy resulted in 50% fewer failures of surveillance and less progression to higher-grade cancer. This confirms the value of MRI in men on surveillance. This study is registered at ClinicalTrials.gov (NCT01354171).

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Klotz L, Pond G, Loblaw A, et al. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. Eur Urol. 2019. PMID: 31708295. doi:10.1016/j.eururo.2019.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。